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Introduction
A balance between bone formation, performed by osteo-
blasts, and bone resorption, performed by osteoclasts, 
regulates developmental bone remodelling and maintains 
bone integrity throughout life. Pathological bone loss 
occurs when this homeostatic relationship is disturbed. 
Over-activation of osteoclasts is directly responsible for the 
resorptive bone loss evident in diseases such as rheumatoid 
arthritis [1, 2], cancer metastasis to bone [3] and osteopo-
rosis [4].
Micro-environmental hypoxia is a common feature of 
these osteolytic conditions, in all of which hypoxia and / 
or stabilisation of hypoxia-inducible factor (HIF) correlates 
with disease progression and poor prognosis [5–7]. HIF is 
a heterodimeric transcription factor, the stability and tran-
scriptional activity of which is controlled via regulation of 
the hypoxia-inducible alpha subunits (HIF-1α, HIF-2α). In 
normoxic conditions HIF-α is post-translationally hydroxy-
lated by a set of three oxygen-dependent prolyl hydroxylase 
domain enzymes (PHD1-3), targeting it for proteasomal 
degradation. An additional regulatory enzyme, asparagine 
hydroxylase factor inhibiting HIF (FIH), inhibits the tran-
scriptional activity of any remaining HIF. Activity of the 
HIF hydroxylases is limited by oxygen deficiency, allow-
ing hypoxic stabilisation of HIF-α and binding of the active 
HIF complex to the hypoxia-response element (HRE) of 
HIF target genes [8].
Hypoxia causes a HIF-1α-dependent increase in the abil-
ity of in  vitro cultured osteoclasts to resorb bone [9–11]. 
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Using osteoclast-specific conditional HIF-1α knockout 
mice, it was also shown that HIF-1α is essential for driv-
ing the resorptive bone loss associated with the osteoporo-
tic phenotype in ovariectomised mice [7]. To identify the 
genes and pathways driving the hypoxic increase in bone 
resorption, we previously performed a microarray compar-
ing gene expression in normoxic versus hypoxic (24 h, 2% 
 O2) osteoclasts [11]. This led to the identification of pro-
resorptive effects for the adipocytokine angiopoietin-like 4 
(ANGPTL4) [11, 12] and for the metabolic enzymes regu-
lating hypoxic production of ATP [13].
Another gene of interest from the microarray was 
fibroblast growth factor 11 (FGF11), also known as FGF 
homologous factor 3 (FHF3), which belongs to the fam-
ily of intracellular non-secreted FGFs that includes FGF12 
(FHF1), FGF13 (FHF2) and FGF14 (FHF4). These intra-
cellular FGFs do not bind either the classical FGF receptors 
or heparan sulphate glycosaminoglycans and are thought 
to bind target proteins distinct from those of the classical 
FGFs [14]. While cytoplasmic binding partners have been 
suggested for the other FHFs, including the MAPK scaffold 
protein islet-brain 2 (IB2) [15], voltage-gated sodium chan-
nels [16, 17] and cardiac calcium channels [18], no interac-
tion partner has been described for FGF11.
Similarly, little is known about the function of FGF11. 
Fgf11 mRNA expression was described in the epithelial 
signalling centres and epithelial-mesenchymal interfaces at 
key stages of mouse tooth formation, suggestive of a role 
in odontogenesis [19]. Fgf11 mRNA was also elevated 
during a full-thickness mouse skin wound healing experi-
ment [20] and in fibroblasts seeded in vitro into a fibrous 
hydrogel scaffold to support skin repair [21]. Additionally, 
FGF11 over-expression in endothelial cells stimulated cap-
illary-like tube formation in vitro [22]. A developmental or 
tissue remodelling role for FGF11 therefore seems likely. 
This study aims to investigate the mechanism of induction 
of FGF11 in hypoxic osteoclasts and to identify any effects 




Peripheral blood mononuclear cells (PBMCs) were isolated 
from leucocyte cones using Histopaque (Sigma). Posi-
tively selected CD14+ monocytes were seeded onto tissue 
culture plates or dentine slices in α-MEM culture media 
(without ribonucleosides/deoxyribonucleosides) contain-
ing 10% FBS, L-glutamine (2 mM), penicillin (50  IU/ml) 
and streptomycin sulphate (50 μg/ml). Cultures were sup-
plemented with M-CSF (25  ng/ml) + RANKL (35  ng/ml) 
every 3–4  days, with mature osteoclasts being formed by 
day 9. Antibodies were against the vitronectin receptor 
(VNR) (CD51/61 monoclonal antibody, AbD Serotec) and 
alpha-tubulin (4a, GeneTex). F-actin was visualised using 
TRITC-phalloidin. Multinucleated cells containing ≥3 
nuclei were considered osteoclasts. Resorption pits were 
stained with 0.5% toluidine blue, photographed and quanti-
fied using ImageJ.
Cell Culture
THP1 (monocytic leukaemia), Jurkat (T cell leukae-
mia), MG-63 and Saos2 (osteoblastic osteosarcoma) cell 
lines were maintained in RPMI 1640 supplemented with 
10% FBS, L-glutamine (2  mM), penicillin (50  IU/ml) 
and streptomycin sulphate (50  μg/ml). Primary human 
CD14+ monocytes were separated from PBMCs and main-
tained in αMEM supplemented with 25  ng/ml M-CSF. 
CD4+ T cells were positively selected from the same 
PBMCs. Primary human osteoblasts were obtained by out-
growth from cancellous bone chips removed during sur-
gery. Mononuclear GCTB stromal cells were isolated from 
GCTB as described previously [23]. Mouse bone marrow 
cells were flushed from the long bones of C57BL/6 wild-
type and  PHD2+/− mice [24] and cultured in αMEM sup-
plemented with 25  ng/ml M-CSF for 2  days. Hypoxic 
exposure (2%  O2, 5%  CO2, balance  N2) was performed in a 
MiniGalaxy incubator.
Real-Time PCR
RNA was extracted in TRI reagent then DNase-treated 
and eluted using the Direct-Zol RNA Miniprep kit (Zymo 
Research). RNA was reverse-transcribed and then real-time 
PCR was performed with Fast SYBR Green Master Mix 
(Applied Biosystems) and human QuantiTect primers (Qia-
gen). Primers were designed in-house to murine Fgf11; S: 
5′-CCA GCT CCT TCA CCC ACT TC-3′, AS: 5′-CAA TAG 
CCC CTC AGC GTT CA-3′ and murine Actb; S: 5′-ATG TGG 
ATC AGC AAG CAG GAG-3′, AS: 5′-GTG TAA AAC GCA 
GCT CAG TAACA-3′. Comparative quantification was per-
formed, with target gene expression normalized to β-actin 
(Actb).
Western Blot Analysis and ELISA
Cells were homogenized in lysis buffer (6.2 M urea, 10% 
glycerol, 5  mM DTT, 1% SDS, protease inhibitors). Pri-
mary antibodies were against FGF11 (ab129375, Abcam), 
HIF-1α (clone 54; BD Biosciences), MMP9 (EP1254, 
Abcam) and β-tubulin (TUB2.1, Sigma). Images were 
either scanned from X-ray film or acquired using the Uvitec 
Alliance imaging system and NineAlliance software. 
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Densitometry was performed in ImageJ and normalized 
to the β-tubulin signal. ELISA kits were against FGF11 
(USCNK) and ANGPTL4 (R&D Systems).
Plasmid Cloning and siRNA Transfection
Mature osteoclasts were transfected with 50  nM siRNA 
targeting HIF-1α or a HIF-1α scrambled control [25] or 
with Silencer Select Pre-designed siRNA targeting FGF11 
(s5152 [F2] and s5153 [F3]) or a negative control (Ambion) 
using RNAiMAX (Invitrogen). Duplexes were removed 
after 4 h and osteoclasts incubated in osteoclast differentia-
tion media. Human FGF11 (TrueClone Full-Length cDNA, 
OriGene) was cloned into pcDNA3 using EcoRI and NotI. 
The FGF11-pcDNA3 expression construct was transfected 
into MG-63 cells using Lipofectamine 2000 (Invitrogen).
Metabolic Assays
Glucose was measured in cell culture medium using the 
Glucose (GO) Assay Kit (Sigma). Mitochondrial dehydro-
genase activity was assessed using Alamar blue (AbD Sero-
tec). All results were normalized to cell number determined 
using crystal violet, which stains nuclei independently of 
cellular metabolic status, which was then extracted and 
absorbance read at 550 nm.
Immunohistochemistry
Human tissue sections were obtained from the Oxford 
Musculoskeletal Biobank (OMB); the study was approved 
under OMB ethics (HTA Licence 12217, Oxfordshire 
Research Ethics Committee C, 09/H0606/11) and carried 
out in accordance with the associated guidelines and regu-
lations. Informed consent was obtained from all subjects. 
GCTB tissue (n = 5 tumours) and RA tissue (n = 3 sam-
ples) was from samples previously identified as contain-
ing HIF-positive osteoclasts [12, 26]. Antigen retrieval of 
deparaffinised formalin-fixed tissue sections was performed 
by microwaving in 1  mM EDTA (pH 8). Sections were 
exposed to anti-FGF11 antibody (ab129375, Abcam) with 
normal rabbit serum as a negative control. Staining was 
visualised with the VECTASTAIN Elite ABC Kit (Vector 
Laboratories). Osteoclasts in tissue sections were classified 
as large, multinucleated cells containing  ≥3 nuclei.
Statistics
Results are represented as mean ± standard error of at least 
n = 3 independent experiments. Statistical analysis com-
prises one-way or two-way ANOVA using Dunnett’s com-
parison as a post hoc test. For experiments with only two 
conditions, a Students’s t test was applied. Results were 
considered significant at values of p < 0.05.
Results
FGF11 Expression is Induced by Hypoxia
Fgf11 (NM_004112.2) exhibited 4.7-fold hypoxic induc-
tion (p < 0.00001) in our published microarray comparing 
gene expression in normoxic versus hypoxic (24 h, 2%  O2) 
osteoclasts [11]. Induction of Fgf11 by 24 h exposure to 2% 
 O2 was confirmed in in  vitro differentiated osteoclasts by 
real-time PCR (Fig. 1a), hypoxic culture conditions being 
confirmed by parallel induction of two established hypoxia-
regulated genes (Slc2a1, Ldha).
Hypoxic induction of FGF11 protein was observed by 
Western blot after 24 h exposure to 2%  O2 (Fig. 1b), with 
hypoxic culture conditions being confirmed by stabilisation 
of HIF-1α protein.
Densitometry indicated a hypoxic induction of 3.36-
fold ± 0.81 (p < 0.05) for FGF11 protein. Hypoxia-induci-
ble bands were detected with molecular weights of approxi-
mately 20 and 24 kDa. Transfection of a full-length human 
FGF11 construct into MG-63 cells produced FGF11 protein 
running at 24 kDa, suggesting that the 20 kDa form could 
be the result of alternative post-translational processing of 
FGF11 in osteoclasts (Fig.  1c). No FGF11 was detected 
in the conditioned media of either hypoxic osteoclasts or 
MG-63 transfectants by either Western blot or ELISA, con-
sistent with FGF11 being an intracellular FGF.
To compare levels of expression of Fgf11 mRNA in 
other bone-related cell types, we exposed primary osteo-
clasts, monocytes, T cells and osteoblasts, as well as 
associated cell lines, to normoxia and hypoxia for 24  h 
(Fig.  1d). Primary cells showed much higher levels of 
Fgf11 mRNA than cell lines of the same origin. Osteo-
clasts and the CD14+ monocytes from which they derive 
expressed similar levels of Fgf11. However, CD4+ T cells 
had the highest expression of Fgf11 in both normoxic and 
hypoxic conditions. Normoxic expression of FGF11 protein 
was confirmed in CD4+ T cells by Western blot, as well as 
a striking hypoxic induction (Fig. 1e).
Hypoxic Induction of FGF11 is Regulated by HIF-1α
Yang et al. recently described HIF-1α-dependent activation 
of two HREs in the FGF11 promoter, using co-transfection 
of promoter luciferase constructs and HIF-1α over-expres-
sion plasmids into endothelial cells (HUVEC) [22]. We 
therefore investigated whether hypoxic induction of FGF11 
was also HIF-1α-dependent in osteoclasts.
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Normoxic stabilisation of HIF-1α by  CoCl2 or desfer-
rioxamine (DFO) increased expression of Fgf11 mRNA 
(Fig.  2a) and FGF11 protein (Fig.  2b) in primary human 
osteoclasts. As neither stimulus specifically inhibits the 
HIF-regulating PHD enzymes, we also investigated effects 
of genetic inactivation of PHD2, the primary regulator of 
HIF instability in normoxia [27]. Fgf11 mRNA expression 
was elevated in the bone marrow cells of  PHD2+/− mice in 
comparison with wild-type littermate controls (Fig.  2c). 
Treatment of osteoclasts with isoform-specific siRNA 
targeting either HIF-1α or HIF-2α revealed that hypoxic 
induction of Fgf11 mRNA is regulated by HIF-1α, in a 
similar manner to the known HIF-1α target gene Slc2a1 
(Fig. 2d).
FGF11 Mediates Hypoxic Induction 
of Osteoclast-Mediated Bone Resorption
To determine whether FGF11 affects osteoclast function, 
mature osteoclasts were transfected with two independ-
ent siRNAs targeting FGF11 (F2 and F3) or a negative 
control siRNA (neg). Both FGF11 siRNAs completely 
ablated the hypoxic increase in Fgf11 mRNA (Fig. 3a) and 
dramatically reduced hypoxic induction of FGF11 protein 
(Fig. 3b). FGF11 siRNA did not significantly affect osteo-
clast number in either normoxic or hypoxic (24 h, 2%  O2) 
conditions (Fig. 3c). However, knock-down of FGF11 did 
reduce the hypoxic increase in osteoclast-mediated bone 
resorption by 73.8% (F2 siRNA) and 82.1% (F3 siRNA), 
respectively, (Fig. 3d, e), without affecting normoxic levels 
of resorption.
Mechanism of Action for FGF11-Mediated Bone 
Resorption
As there are no known interaction partners for FGF11, 
we next investigated whether FGF11 modulates pathways 
already known to mediate the hypoxic induction of bone 
resorption by osteoclasts. However, FGF11 siRNA did 
not affect the hypoxic increase in either glucose consump-
tion (Fig. 4a) or mitochondrial reductase activity (Fig. 4b) 
observed in osteoclasts. Neither did it affect hypoxic 
expression of the pro-resorptive adipokine ANGPTL4 
(Fig. 4c, d).
To determine whether effects of FGF11 were mediated 
by an intracellular or secreted factor, we collected condi-
tioned media from osteoclasts treated with FGF11 siRNA 
and subsequently exposed to normoxic or hypoxic condi-
tions for 24 h. This conditioned media was then applied to 
fresh mature osteoclasts for a further 24 h. No conditioned 
media had any effect on osteoclast number (Fig.  4e), but 
hypoxic control media caused a twofold increase in bone 
resorption that did not occur with media from FGF11 
siRNA-treated osteoclasts (Fig.  4f). FGF11 has been pro-
posed to promote matrix metalloproteinase 9 (MMP9) sig-
nalling in T cells [28]. However, no effect of FGF11 siRNA 
Fig. 1  a Comparative quantitation of Fgf11, Slc2a1 and Ldha mRNA 
in mature human osteoclasts following 24  h exposure to normoxia 
or hypoxia (2%  O2) (Slc2a1 = solute carrier family 2 member 1/glu-
cose transporter 1 (Glut-1), Ldha = lactate dehydrogenase A, Actb = 
β-actin). *p < 0.05; **p < 0.01. b Expression of HIF-1α and FGF11 
protein in two independent osteoclast populations (OC-1, OC-2) after 
24 h exposure to normoxia (Nx) or hypoxia (2%  O2, Hx). c Expres-
sion of FGF11 protein in MG-63 cells 72  h after transfection with 
FGF11-pcDNA3 (FGF-11) or an empty vector (EV) control. d Com-
parative quantitation of Fgf11 mRNA in multiple cell types (OC, 
primary osteoclasts; MON, CD14+ monocytes; THP1, monocytic 
cell line; T cell, CD4+ T cell; Jurkat, T cell line; OB, primary human 
osteoblasts; GCTB, stromal cells from Giant Cell Tumour of Bone, 
MG-63 and Saos2, osteoblastic cell lines) following 24 h exposure to 
normoxia or hypoxia (2%  O2). **p > 0.01; ***p < 0.001. e Expression 
of FGF11 protein in two independent CD4+ T cell populations (CD4-




Fig. 2  Comparative expression of a Fgf11 mRNA and b FGF11 pro-
tein in mature human osteoclasts following 24  h exposure to  CoCl2 
(100 μM) or desferrioxamine (DFO, 100 μM). c Comparative quan-
titation of Fgf11 mRNA in PHD2 wild-type and  PHD2+/− bone mar-
row cells. d Effect of siRNA targeting HIF-1α or HIF-2α, or a HIF-1α 
scrambled control (scr), on expression of HIF-1α, HIF-2α, Slc2a1 or 
Fgf11 mRNA. *p < 0.05; **p > 0.01; ***p < 0.001
Fig. 3  Comparative quantitation of a Fgf11 mRNA and b FGF11 
protein in mature human osteoclasts treated with siRNA targeting 
FGF11 (F2, F3) or a negative control siRNA (neg) followed by 24 h 
exposure to hypoxia (2%  O2). Densitometry was used to quantify per-
centage reduction in hypoxic FGF11 protein due to siRNA treatment. 
c Quantification of the number of VNR-positive, multinucleated oste-
oclasts and d quantified resorption (resorption track area per osteo-
clast) following treatment with FGF11 or negative control siRNA and 
24 h exposure to either normoxia or hypoxia (2%  O2). e Representa-
tive dentine slices showing toluidine blue-stained resorption tracks. 
*p < 0.05; **p > 0.01; ***p < 0.001




























































































































































































































































































































































was observed on hypoxic expression of either MMP9 
mRNA (Fig. 4g) or protein (Fig. 4h).
As the available literature suggests a developmental or 
tissue remodelling role for FGF11 [19–22], we also exam-
ined the intracellular distribution of this FGF. Osteoclasts 
cultured on glass coverslips exhibited a diffuse FGF11 
immunoreactivity in normoxia which intensified in the 
peri-nuclear region following hypoxic exposure (Fig.  5a). 
Hypoxic exposure was confirmed by staining for HIF-1α. 
This pattern of FGF11 immunostaining was reminiscent 
of the pattern of global alpha-tubulin staining that repre-
sents the microtubule arrangements observed in quiescent 
versus resorbing osteoclasts Lakkakorpi and Vaananen 
described microtubules in quiescent osteoclasts as being 
spread evenly over the whole cell, whereas those in resorb-
ing osteoclasts were concentrated centrally over the resorp-
tion lacunae [29]. We also observed this pattern of alpha-
tubulin staining in normoxic versus hypoxic osteoclasts 
(Fig.  5b). Fluorescent double staining for FGF11 and 
α-tubulin revealed co-localisation of the proteins in the cen-
tral, peri-nuclear region of hypoxic osteoclasts (Fig.  5b). 
The normoxic signal for FGF11 was too weak to determine 
whether this co-localisation also occurs in normoxia. When 
FGF11 immunostaining was performed on osteoclasts cul-
tured on dentine slices, the central concentration of FGF11 
above resorption lacunae was clearly evident (Fig. 5c).
FGF11 was also expressed by the osteoclasts present in 
pathological conditions associated with excessive levels 
of osteoclast-mediated osteolysis. FGF11 expression was 
evident in large multinucleated cells morphologically 
resembling osteoclasts in representative cases of rheuma-
toid arthritis (RA) and giant cell tumour of bone (GCTB) 
(Fig. 5d).
Discussion
Inhibition of osteoclast-mediated bone resorption is a ther-
apeutic strategy to prevent pathological bone loss in condi-
tions including rheumatoid arthritis, primary bone cancer, 
bone-metastatic cancer and osteoporosis. Over-expression 
of HIF-1α is a common feature of these conditions, associ-
ated with poor prognosis. Here, we describe FGF11 as a 
hypoxia- and HIF-1α-regulated gene in osteoclasts, which 
additionally drives hypoxic stimulation of osteoclast-medi-
ated bone resorption.
Hypoxic induction of FGF11 mRNA and protein was 
observed in primary monocyte-derived osteoclasts and 
CD4+ T cells. FGF11 induction by PHD2 inhibition 
implied a role for HIF in this process, as was subsequently 
confirmed by HIF-1α siRNA. This is in agreement with 
Yang et  al., who recently identified two HIF-1α-driven 
HREs in the FGF11 promoter in HUVEC [22]. However, 
it is noteworthy that FGF11 is generally not described in 
numerous studies performing genome-wide screening for 
HIF target genes [30–33]. Indeed, the only hit we found 
Fig. 5  a Multi-nuclear mature human osteoclasts cultured on glass 
coverslips were exposed to normoxia or hypoxia (2%  O2) for 24 h and 
stained for FGF11 or HIF-1α. b Mature osteoclasts cultured on glass 
coverslips were stained for total alpha-tubulin (green), F-actin (red) 
or FGF11 (red) following 24 h exposure to normoxia or hypoxia (2% 
 O2). Nuclei were visualised with DAPI (4′,6-diamidino-2-phenylin-
dole). c Actively resorbing FGF11-positive osteoclasts cultured on 
dentine discs reside above lacunar resorption pits (single asterisk). d 
FGF11 is strongly expressed by osteoclasts in representative images 
of the rheumatoid synovium (RA) and giant cell tumour of bone 
(GCTB)
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for FGF11 was reached using a computational strategy 
to combine transcriptional profiling meta-analysis of 
hypoxia-modulated genes with identification of HIF bind-
ing sites within potential cis-regulatory regions [34]. The 
reason for this is unclear but may indicate either a lim-
ited cell / tissue expression profile for FGF11 or reduced 
expression in the immortalised cell lines in which most 
screens are performed.
As hypoxic stimulation of osteoclast-mediated bone 
resorption is HIF-1α-dependent [10], we next sought to 
determine whether elevated expression of FGF11 could 
contribute to this response. siRNA targeting FGF11 sig-
nificantly diminished the hypoxic increase in resorption. 
Conditioned media from hypoxic osteoclasts also stimu-
lated bone resorption and this effect was also lost when 
the conditioned media was from FGF11 siRNA-treated 
osteoclasts. As FGF11 is an intracellular FGF, this must 
occur due to induction of a secreted factor downstream 
of FGF11. Few cytokines or growth factors have been 
described that can enhance bone resorption independ-
ent of effects on osteoclastogenesis. The main candidates 
are RANKL [35] and ANGPTL4 [11], however, RANKL 
is not produced by osteoclasts and ANGPTL4 expres-
sion was not modulated by FGF11. Hu et  al. described 
FGF11-mediated stimulation of MMP9 production by 
prostate cancer cells [28]. However, the proposed mecha-
nism involved secretion of FGF11 from infiltrating T 
cells, which should not occur. Regardless of the T cell / 
prostate cancer mechanism, MMP9 expression by osteo-
clasts was also not modulated by FGF11.
Although described as intracellular, it has been hypoth-
esised that FGF11 could potentially be released from cells 
by a mechanism(s) independent of the endoplasmic reticu-
lum and Golgi apparatus [14, 36]. FGF11 (and the other 
FHFs) does not possess a secretory signal sequence, but 
contains a nuclear localisation signal (NLS)-like sequence 
and is not secreted from transfected cell lines [36, 37]. 
However, these characteristics are shared with prototypical 
FGF1 and FGF2, which can be released from cells during 
cell migration [38] and via the Na+, K+-ATPase ion trans-
porter [39]. These mechanisms are both directly relevant to 
osteoclast-mediated bone resorption, which relies heavily 
on both cell migration [40] and extracellular acidification 
by active transport of protons across the bone-apposing 
membrane [41]. However, we were unable to detect FGF11 
in the conditioned media of either hypoxic osteoclasts or 
FGF11-transfected MG-63 cells by either Western blot or 
ELISA. It is possible that the concentration of secreted 
FGF11 was below the detection limit of our assays, in 
which case FGF11 itself might mediate the effects of 
hypoxic osteoclast conditioned media to stimulate bone 
resorption. However, there is currently no evidence avail-
able that this secretory mechanism(s) occurs for FGF11.
The small volume of literature available on FGF11 
currently suggests a tissue remodelling function for this 
growth factor, with roles described in endothelial tube 
formation [22], odontogenesis [19] and skin wound heal-
ing [20, 21]. We therefore examined the intracellular dis-
tribution of FGF11 and observed the majority of FGF11 
immunoreactivity in the central peri-nuclear region of 
the cell where it co-localised with α-tubulin, especially 
in actively resorbing hypoxic osteoclasts. This central 
concentration of microtubules over the resorption lacu-
nae has been proposed to reflect the secretory function 
of resorbing osteoclasts [29]. Transcytotic vesicles con-
taining the degraded bone matrix are associated with 
microtubules in bone-resorbing osteoclasts, suggesting 
that intracellular transport of transcytotic vesicles is sup-
ported by microtubules [42, 43]. It is therefore possible 
that FGF11 exerts its effect on bone resorption by interac-
tion with α-tubulin or other microtubule-associated pro-
teins. Alternatively, FGF11 might affect the expression or 
function of proteins that form the sealing zone in osteo-
clasts. Yang et  al. reported FG11-mediated induction of 
the tight junction proteins occludin, ZO-1 and claudin-5 
in HUVEC cells [22].
It is unfortunate that we were unable to identify a pre-
cise mechanism of action or a specific pathway activated 
downstream of FGF11. Limitations of the commercially 
available FGF11 antibodies precluded immunoprecipita-
tion studies to determine whether FGF11 binds directly to 
α-tubulin or other microtubule-associated proteins. Addi-
tionally, the scale of screening we were able to perform 
was unable to identify either the secreted pro-resorptive 
factor induced by FGF11 or other intracellular signalling 
pathways activated by FGF11. However, it is hoped that 
our description of hypoxia-inducible, HIF-1α-regulated 
expression of FGF11 in osteoclasts and a role for FGF11 
in mediating increased osteoclast-mediated bone resorp-
tion under hypoxic conditions will encourage further 
research on this intriguing growth factor.
The novel pro-resorptive function for FGF11 described 
here adds weight to the presumptive tissue remodelling 
role(s) of this growth factor. As it is also expressed in the 
osteoclasts associated with pathological bone resorption 
conditions such as rheumatoid arthritis, it represents a 
potential novel modulator of excessive osteolysis. Studies 
to further delineate the function(s) and signalling path-
ways involved in FGF11 biology may reveal exciting new 
therapeutic opportunities.
Acknowledgements This work was supported by Arthritis Research 
UK (MP/19200), The Rosetrees Trust (M456) and the Oxford 
National Institute of Health Research (NIHR) Musculoskeletal Bio-
medical Research Unit (BRU). Thanks go to Professor Nick Athana-
sou for critical reading of the manuscript.
390 H. J. Knowles 
1 3
Compliance with Ethical Standards 
Conflict of interest The author reports no conflicts of interest.
Human and Animal Rights and Informed Consent All animal 
procedures were carried out in accordance with the guidelines and 
regulations of the UK Home Office Animals (Scientific Procedures) 
Act 1986. All experimental protocols were approved by the University 
of Oxford Medical Sciences Division Ethical Review Committee.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted 
use, distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Bromley M, Woolley DE (1984) Chondroclasts and osteoclasts 
at subchondral sites of erosion in the rheumatoid joint. Arthritis 
Rheum 27(9):968–975
 2. Gough A, Sambrook P, Devlin J, Huissoon A, Njeh C, Robbins 
S, Nguyen T, Emery P (1998) Osteoclastic activation is the prin-
cipal mechanism leading to secondary osteoporosis in rheuma-
toid arthritis. J Rheumatol 25(7):1282–1289
 3. Krzeszinski JY, Wan Y (2015) New therapeutic targets for can-
cer bone metastasis. Trends Pharmacol Sci 36(6):360–373
 4. Tella SH, Gallagher JC (2014) Biological agents in management 
of osteoporosis. Eur J Clin Pharmacol 70(11):1291–1301
 5. Zhao X, Yue Y, Cheng W, Li J, Hu Y, qin L, Zhang PZ (2013) 
Hypoxia-inducible factor: a potential therapeutic target for rheu-
matoid arthritis. Curr Drug Targets 14(6):700–707
 6. Rankin EB, Giaccia AJ (2016) Hypoxic control of metastasis. 
Science 352(6282):175–180
 7. Miyauchi Y, Sato Y, Kobayashi T, Yoshida S, Mori T, Kanagawa 
H, Katsuyama E, Fujie A, Hao W, Miyamoto K, Tando T, 
Morioka H, Matsumoto M, Chambon P, Johnson RS, Kato S, 
Toyama Y, Miyamoto T (2013) HIF1alpha is required for osteo-
clast activation by estrogen deficiency in postmenopausal osteo-
porosis. Proc Natl Acad Sci USA 110(41):16568–16573
 8. Kaelin WG Jr, Ratcliffe PJ (2008) Oxygen sensing by metazo-
ans: the central role of the HIF hydroxylase pathway. Mol Cell 
30(4):393–402
 9. Muzylak M, Price JS, Horton MA (2006) Hypoxia induces giant 
osteoclast formation and extensive bone resorption in the cat. 
Calcif Tissue Int 79(5):301–309
 10. Knowles HJ, Athanasou NA (2009) Acute hypoxia and osteoclast 
activity: a balance between enhanced resorption and increased 
apoptosis. J Pathol 218(2):256–264
 11. Knowles HJ, Cleton-Jansen AM, Korsching E, Athanasou NA 
(2010) Hypoxia-inducible factor regulates osteoclast-medi-
ated bone resorption: role of angiopoietin-like 4. FASEB J 
24(12):4648-
 12. Swales C, Athanasou NA, Knowles HJ (2014) Angiopoietin-like 
4 is over-expressed in rheumatoid arthritis patients: association 
with pathological bone resorption. PLoS One 9(10):e109524
 13. Morten KJ, Badder L, Knowles HJ (2013) Differential regula-
tion of HIF-mediated pathways increases mitochondrial metab-
olism and ATP production in hypoxic osteoclasts. J Pathol 
229(5):755–764
 14. Olsen SK, Garbi M, Zampieri N, Eliseenkova AV, Ornitz DM, 
Goldfarb M, Mohammadi M (2003) Fibroblast growth factor 
(FGF) homologous factors share structural but not functional 
homology with FGFs. J Biol Chem 278(36):34226–34236
 15. Schoorlemmer J, Goldfarb M (2001) Fibroblast growth factor 
homologous factors are intracellular signaling proteins. Curr 
Biol 11(10):793–797
 16. Liu CJ, Dib-Hajj SD, Renganathan M, Cummins TR, Waxman 
SG (2003) Modulation of the cardiac sodium channel Nav1.5 
by fibroblast growth factor homologous factor 1B. J Biol Chem 
278(2):1029–1036
 17. Wang C, Wang C, Hoch EG, Pitt GS (2011) Identification of 
novel interaction sites that determine specificity between fibro-
blast growth factor homologous factors and voltage-gated 
sodium channels. J Biol Chem 286(27):24253–24263
 18. Hennessey JA, Wei EQ, Pitt GS (2013) Fibroblast growth fac-
tor homologous factors modulate cardiac calcium channels. Circ 
Res 113(4):381–388
 19. Kettunen P, Furmanek T, Chaulagain R, Kvinnsland IH, Luukko 
K (2011) Developmentally regulated expression of intracellular 
Fgf11-13, hormone-like Fgf15 and canonical Fgf16, -17 and -20 
mRNAs in the developing mouse molar tooth. Acta Odont Scand 
69(6):360–366
 20. Komi-Kuramochi A, Kawano M, Oda Y, Asada M, Suzuki M, 
Oki J, Imamura T (2005) Expression of fibroblast growth factors 
and their receptors during full-thickness skin wound healing in 
young and aged mice. J Endocrinol 186(2):273–289
 21. Lin HY, Peng CW, Wu WW (2014) Fibrous hydrogel scaffolds 
with cells embedded in the fibers as a potential tissue scaffold for 
skin repair. J Mat Sci 25(1):259–269
 22. Yang J, Kim WJ, Jun HO, Lee EJ, Lee KW, Jeong JY, Lee SW 
(2015) Hypoxia-induced fibroblast growth factor 11 stimu-
lates capillary-like endothelial tube formation. Oncol Rep 
34(5):2745–2751
 23. Lau YS, Sabokbar A, Gibbons CL, Giele H, Athanasou N (2005) 
Phenotypic and molecular studies of giant-cell tumors of bone 
and soft tissue. Hum Pathol 36(9):945–954
 24. Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, 
Jonckx B, Tian YM, Lanahan AA, Pollard P, Ruiz de Almodo-
var C, De Smet F, Vinckier S, Aragones J, Debackere K, Luttun 
A, Wyns S, Jordan B, Pisacane A, Gallez B, Lampugnani MG, 
Dejana E, Simons M, Ratcliffe P, Maxwell P, Carmeliet P (2009) 
Heterozygous deficiency of PHD2 restores tumor oxygena-
tion and inhibits metastasis via endothelial normalization. Cell 
136(5):839–851
 25. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL 
(2003) Predominant role of hypoxia-inducible transcription fac-
tor (Hif)-1alpha versus Hif-2alpha in regulation of the transcrip-
tional response to hypoxia. Cancer Res 63(19):6130–6134
 26. Knowles HJ, Athanasou NA (2008) Hypoxia-inducible factor is 
expressed in giant cell tumour of bone and mediates paracrine 
effects of hypoxia on monocyte-osteoclast differentiation via 
induction of VEGF. J Pathol 215(1):56–66
 27. Meneses AM, Wielockx B (2016) PHD2: from hypoxia regula-
tion to disease progression. Hypoxia 4:53–67
 28. Hu S, Li L, Yeh S, Cui Y, Li X, Chang HC, Jin J, Chang C 
(2015) Infiltrating T cells promote prostate cancer metastasis 
via modulation of FGF11–>miRNA-541–>androgen receptor 
(AR)–>MMP9 signaling. Mol Oncol 9(1):44–57
 29. Lakkakorpi PT, Vaananen HK (1991) Kinetics of the osteoclast 
cytoskeleton during the resorption cycle in vitro. J Bone Miner 
Res 6(8):817–826
 30. Benita Y, Kikuchi H, Smith AD, Zhang MQ, Chung DC, Xavier 
RJ (2009) An integrative genomics approach identifies hypoxia 
inducible factor-1 (HIF-1)-target genes that form the core 
response to hypoxia. Nucleic Acids Res 37(14):4587–4602
391Hypoxia-Induced Fibroblast Growth Factor 11 Stimulates Osteoclast-Mediated Resorption…
1 3
 31. Wenger RH, Stiehl DP, Camenisch G (2005) Integration of oxy-
gen signaling at the consensus HRE. Science’s STKE (306):re12. 
doi:10.1126/stke.3062005re12
 32. Schodel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe 
PJ, Mole DR (2011) High-resolution genome-wide mapping of 
HIF-binding sites by ChIP-sEq. Blood 117(23):e207–e217
 33. Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, 
Ragoussis J, Ratcliffe PJ (2009) Genome-wide association of 
hypoxia-inducible factor (HIF)-1 alpha and HIF-2 alpha DNA 
binding with expression profiling of hypoxia-inducible tran-
scripts. J Biol Chem 284(25):16767–16775
 34. Ortiz-Barahona A, Villar D, Pescador N, Amigo J, del Peso L 
(2010) Genome-wide identification of hypoxia-inducible factor 
binding sites and target genes by a probabilistic model integrat-
ing transcription-profiling data and in silico binding site predic-
tion. Nucleic Acids Res 38(7):2332–2345
 35. Fuller K, Kirstein B, Chambers TJ (2007) Regulation and enzy-
matic basis of bone resorption by human osteoclasts. Clin Sci 
(Lond) 112(11):567–575
 36. Smallwood PM, Munoz-Sanjuan I, Tong P, Macke JP, Hendry 
SH, Gilbert DJ, Copeland NG, Jenkins NA, Nathans J (1996) 
Fibroblast growth factor (FGF) homologous factors: new mem-
bers of the FGF family implicated in nervous system develop-
ment. Proc Natl Acad Sci USA 93(18):9850–9857
 37. Wang Q, McEwen DG, Ornitz DM (2000) Subcellular and 
developmental expression of alternatively spliced forms of fibro-
blast growth factor 14. Mech Dev 90(2):283–287
 38. Mignatti P, Morimoto T, Rifkin DB (1991) Basic fibroblast 
growth factor released by single, isolated cells stimulates their 
migration in an autocrine manner. Proc Natl Acad Sci USA 
88(24):11007–11011
 39. Florkiewicz RZ, Anchin J, Baird A (1998) The inhibition of 
fibroblast growth factor-2 export by cardenolides implies a novel 
function for the catalytic subunit of Na+,K+-ATPase. J Biol 
Chem 273(1):544–551
 40. Teitelbaum SL, Ross FP (2003) Genetic regulation of osteoclast 
development and function. Nat Rev Genet 4(8):638–649
 41. Francis MJ, Lees RL, Trujillo E, Martin-Vasallo P, Heersche JN, 
Mobasheri A (2002) ATPase pumps in osteoclasts and osteo-
blasts. Int J Biochem Cell Biol 34(5):459–476
 42. Mulari MT, Zhao H, Lakkakorpi PT, Vaananen HK (2003) Oste-
oclast ruffled border has distinct subdomains for secretion and 
degraded matrix uptake. Traffic 4(2):113–125
 43. Okumura S, Mizoguchi T, Sato N, Yamaki M, Kobayashi Y, 
Yamauchi H, Ozawa H, Udagawa N, Takahashi N (2006) Coor-
dination of microtubules and the actin cytoskeleton is important 
in osteoclast function, but calcitonin disrupts sealing zones with-
out affecting microtubule networks. Bone 39(4):684–693
